Chris Hatwig has served as president of Apexus, the nation's leader in the advancement of ambulatory pharmacy solutions and the support of compliant 340B programs, since 2004. Apexus is best known for its role as Health Resources and Services Administration’s contracted 340B Prime Vendor, serving all 340B stakeholders. Recently, Apexus has expanded its service offerings to include the Apexus Manufacturer Refund Service and Acentrus, the health system specialty pharmacy program. Throughout his career, Chris has been committed to developing and implementing solutions to improve efficient access to affordable medications between 340B stakeholders and the patients they support.

Before joining Apexus, Chris was the director of Ambulatory Pharmacy Services and Value Analysis Programs at Parkland Health & Hospital System in Dallas, where he practiced for 13 years, managing one of the nation’s largest and most progressive safety net ambulatory pharmacy programs. Mr. Hatwig received his bachelor’s degree in pharmacy from the University of Arkansas. He completed residencies in hospital pharmacy and hospital pharmacy administration at the University of Wisconsin, culminating in an MS in hospital pharmacy.

Katy received her B.S in Health Administration from Roberts of Wesleyan College in Rochester, NY. Katy is also an Apexus Certified Expert, completing the Apexus Advanced 340B Operations Certificate in 2017. Katy has been with URMC’s pharmacy department for twenty years, the focus of the past ten years has been in the 340B space. As URMC’s 340B Business Manager, Katy provides 340B oversight across the health system. Katy also works closely with UR Government Relations and other safety net providers to advocate for the preservation of the 340B program, meeting with key lawmakers on Capitol Hill on a biannual basis to explain the value of the Program and its importance in stretching scarce resources.

Bachelor of Science in Business Administration from The University of Tennessee and Masters of Business Administration from Philadelphia University. Since 2008, has gained a vast knowledge of the 340B program from the rules and regulations that govern the program to the vendors that provide support services. Has held engagements with: Covered Entities, both hospital and non-hospital, Third party Administrators, Contract Pharmacy Providers, Wholesalers, and Manufacturers. Focused on maintaining the 340B program integrity through effective collaboration between stakeholders.

Mujeeb is a 340B National Account Manager with Genentech (A Member of the Roche Group) and has been in a variety of roles over the past 15 years with the company. Genentech is supportive of the appropriate use of the 340B program to support access to medicines for vulnerable patient populations. To help ensure the long-term sustainability of the Program, he is responsible for managing Genentech’s relationship with 340B hospitals/covered entities and focuses on Program integrity and compliance. Mujeeb’s work includes recovery of ineligible discounts through the informal dispute resolution process, managing self-disclosure letters, and 340B education both internally and external to Genentech.

Based out of Philadelphia with education revolving around pharma and 10 years of professional life sciences experience. Leonard is currently an employee at Jazz Pharmaceuticals in the Contract Operations group where he manages various government contract analytics some of which feeds into Finance’s Gross-To-Net deliverables.

BILL SARRAILLE is a senior member of the Healthcare practice group and a nationally-recognized lawyer in healthcare law. Bill concentrates on a variety of healthcare matters, including Medicare and Medicaid reimbursement, coverage and coding, pharmaceutical price reporting, issues related to the marketing and promotion of pharmaceuticals and medical devices, internal investigations, clinical research issues, Stark and Anti-Kickback Law analyses, Medicare and Medicaid audits, healthcare acquisitions and due diligence, compliance program audits, managed care matters, healthcare contracts, administrative litigation, legislative matters, privacy and security, coverage for new devices and services, the Foreign Corrupt Practices Act, international compliance and healthcare contracting, the representation of witnesses and companies before Congressional Committees, and the defense of healthcare criminal and False Claims Act matters. Bill has defended clients in some of the largest healthcare fraud investigations brought by the U.S. Government.

Bill’s clients have included pharmaceutical companies, biotechnology companies, device and equipment manufacturers, diagnostics manufacturers, academic medical centers, hospitals, health systems, faculty practice plans, durable medical equipment suppliers, healthcare consulting firms, ambulatory surgical centers, physician practice management companies, managed service organizations, managed care organizations, large physician group practices, imaging centers, financial institutions, contract research organizations, and leading healthcare trade associations and professional societies.

Bill is consistently recognized as a leading healthcare lawyer in Chambers USA and LMG Life Sciences. He was named an LMG Life Sciences star in 2013, 2014 and 2015, and has been recognized every year since 2013 in Chambers USA as a leading lawyer both in D.C. and nationwide. Chambers notes that sources describe Bill as a “terrific regulatory healthcare lawyer” with a "wide range of experience” and noted he is “an excellent reimbursement lawyer.” The directory has also described him as “‘an intellectual heavyweight. He is hugely professional on every issue.’” It also listed Bill as “a very good communicator and a trusted adviser.” Recognized in the 2016 edition of Who’s Who Legal: Life Sciences, they noted “He superbly handles all the regulatory issues encountered by his clients.”

Washingtonian magazine includes Bill on its 2013 list of Washington’s Best Lawyers as one of the region’s “best legal minds” in the area of Healthcare Law. He was listed by Nightingale’s Healthcare News as one of ten “Outstanding Practice Lawyers for 2006.” He is the co-author of several books on healthcare. Bill served on the Regulatory Relief Committee for the American Hospital Association and served on the Compliance Advisory Committee for the Healthcare Financial Management Association as its Chairman. He served as a law clerk to the Honorable Harry L. Hupp in the U.S. District Court for the Central District of California in Los Angeles following his graduation from Harvard Law School in 1989.

Shannon Stephenson is the Chief Executive Officer of Cempa Community Care, formerly Chattanooga CARES, in Chattanooga, Tennessee. Shannon comes from a background in regulatory compliance, public health and safety, business administration, and emergency management. Shannon has a proven track record as a pioneer in cultivating the values of an organization to lead it to success. As an innovative and strategic leader, she uses her visionary approach to move the agency forward by developing culture, enhancing communication, creating strong alliances, and building high performing teams in a desirable work environment.

Since arriving in 2015, Shannon has been instrumental in expanding the programs and services offered by Cempa Community Care. After assessing the community needs, Cempa restructured its mission to include Hepatitis C and Sexually Transmitted Infections. This led to the creation of an STI clinic that offers both Hepatitis C and PrEP services. Additionally, the agency expanded its operations and opened a sister site in partnership with East Tennessee State University Center of Excellence. Further strategic initiatives include introducing the Rapid Antiretroviral Program Initiative for new Diagnosis and Rapid Syphilis Testing; enhancing behavioral health and care coordination programs; launching a rural mobile clinic and syringe services program; rebranding the agency; and expanding access in minority communities.

Nationally, she serves as President of the Ryan White Clinics for 340B Access and member of the AIDS United Public Policy Council. Regionally, she serves as the President for the Association of Governmental Accountants and as a board member or committee member with several community based organizations.

Charles is the Director of Pfizer’s Fraud Investigations Group and has responsibility for 340B Program Integrity. He leads a multi-disciplinary team that addresses all 340B remediation efforts. He developed Pfizer’s current 340B remediation program which has been successful in creating value for both the Company and the 340B covered entities. Charles is an APEXUS 340B University facility member and a frequent speaker on 340B remediation from a manufacturer’s perspective.